Resmed (RMD) Liabilities and Shareholders Equity (2010 - 2026)

Resmed's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $8.8 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 16.09% year-over-year to $8.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.8 billion (up 17.25% YoY) and the FY2025 annual result came in at $8.2 billion, up 18.95% from the prior year.
• Liabilities and Shareholders Equity was $8.8 billion for Q1 2026 at Resmed, up from $8.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $8.8 billion in Q1 2026 and bottomed at $4.9 billion in Q1 2022.
• A 5-year average of $7.0 billion and a median of $6.9 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 41.0% — and 2024, when it grew 1.5%.
• Resmed's Liabilities and Shareholders Equity stood at $6.7 billion in 2022, then climbed by 3.43% to $6.9 billion in 2023, then climbed by 3.42% to $7.1 billion in 2024, then advanced by 19.07% to $8.5 billion in 2025, then advanced by 3.3% to $8.8 billion in 2026.
• Business Quant data shows RMD's Liabilities and Shareholders Equity at $8.8 billion in Q1 2026, $8.5 billion in Q4 2025, and $8.3 billion in Q3 2025.